At its investor day on Monday, Roche, the multinational pharmaceutical company headquartered in Basel, unveiled a bold plan to shift more of its research and development work into autonomous artificial‑intelligence (AI) laboratories. The initiative is presented as a way to speed the discovery of new medicines while preserving what the company calls “AI independence” – the ability to develop and control its own AI tools without reliance on external vendors.
Funding and Reallocation
Roche said it expects to free roughly 2 billion Swiss francs (about $2.41 billion) in R&D savings by 2026. Those funds will be redirected to programs and productivity initiatives that support the autonomous‑lab strategy. The company’s executive vice president of Genentech Research and Early Development, Aviv Regev, emphasized that the move is part of a broader effort to make AI an integral part of decision‑making across the pipeline.
AI Impact on Pipeline Decisions
According to Roche, 40 % of pipeline decisions made between the fourth quarter of 2025 and the second quarter of 2026 already involved a tracked AI or computational contribution. The firm also reported that its AI platform, Target Nexus, is on track to influence 80 % of research portfolio decisions by the end of 2026.
Improved Success Rates
Roche highlighted a jump in its Phase III clinical‑trial success rate, which rose to over 80 % year‑to‑date in 2026 from 65 % in 2025. The company attributes part of that improvement to the increased use of AI in target identification, candidate selection and trial design.
Future Goals
Looking ahead, Roche aims to bring up to 20 new molecular entities (NMEs) to market by 2030. The autonomous‑lab program is positioned as a key driver toward that goal, with the expectation that AI‑enabled labs will reduce the time and cost of early‑stage research.
Boston Innovation Center
Roche recently opened a Boston Innovation Center that will focus on applying AI and machine learning to drug development. The center is intended to serve as a hub for collaboration with academic partners, biotech startups and internal research teams, further cementing Roche’s commitment to AI‑first strategies.
Industry Context
The move reflects a growing trend among large pharmaceutical firms to embed AI more deeply into their R&D pipelines. By building autonomous labs, Roche hopes to stay ahead of competitors and maintain a leadership position in the rapidly evolving biotech landscape.
While the company’s plans are ambitious, analysts note that the success of autonomous AI labs will depend on the quality of data, the robustness of algorithms and the ability to integrate AI insights with human expertise. Roche’s transparent reporting of its AI contributions and early success metrics provides a useful benchmark for the industry as it navigates this technological shift.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
